Home › Companies › Viking Therapeutics, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Viking Therapeutics, Inc.’s Form 8-K, filed May 26, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of May 19, 2026: 4 items on Viking Therapeutics, Inc.’s Form 8-K, filed May 26, 2026: 2 approved · 2 passed (calculated).
Significant dissent: 2 directors (49.2%, 33.7% against).
Notable dissent: 1 say-on-pay vote (70.2% support).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Viking Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Viking Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 26, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: J. Matthew Singleton | 28,648,459 | -- | -- | 14,562,012 | 36,879,061 | 66% | Passed (calculated) | — |
| Elect Director: S. Kathryn Rouan, Ph.D. | 21,960,203 | -- | -- | 21,250,268 | 36,879,061 | 50.8% | Passed (calculated) | — |
| 2. To ratify the selection of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2026 | 78,368,957 | 1,241,969 | 478,606 | -- | -- | 98% | Approved | — |
| 3. To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement | 30,045,938 | 12,763,135 | 401,396 | -- | 36,879,063 | 70% | Approved | — |
Source: Viking Therapeutics, Inc., Form 8-K, filed with the SEC on May 26, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
408 asset managers disclosed a vote on at least one Viking Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 8 wordings of this item as funds reported it.
66% Majority: yes · of votes cast
Description as filed by funds: ELECTION OF DIRECTOR NOMINEES FOR CLASS II (term to expire in 2029): J. Matthew Singleton
Viking Therapeutics, Inc.’s own tally for this item (“Elect Director: J. Matthew Singleton”): 28,648,459 for, 14,562,012 withheld, per its Form 8-K filed May 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 66% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 77 asset managers below reported 13,684,558 for, 6,813,572 withheld, 499,807 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,645,406 | 0 | 80 | 6,778 | For |
| Fidelity | 1,700,563 | 0 | 0 | 4,362,187 | Mixed |
| American Century | 0 | 0 | 0 | 937,561 | Withhold |
| Charles Schwab | 707,169 | 0 | 0 | 0 | For |
| BlackRock | 335,565 | 0 | 329,291 | 0 | Mixed |
| Delaware/Macquarie | 0 | 0 | 0 | 330,100 | Withhold |
| JPMorgan | 312,705 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 305,414 | 0 | 0 | 0 | For |
| Principal | 0 | 0 | 0 | 280,964 | Withhold |
| State Street | 190,298 | 0 | 0 | 225 | For |
| TIAA | 184,547 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 0 | 0 | 147,262 | Withhold |
| Jackson National | 53,776 | 0 | 60,430 | 0 | Mixed |
| First Trust | 0 | 0 | 0 | 106,325 | Withhold |
| ALPS ETF Trust | 0 | 0 | 0 | 100,464 | Withhold |
| BARON SELECT FUNDS | 0 | 0 | 0 | 74,811 | Withhold |
| MASTER INVESTMENT PORTFOLIO | 5,873 | 0 | 64,349 | 0 | Mixed |
| Victory Capital | 0 | 0 | 0 | 69,566 | Withhold |
| ProShares | 0 | 0 | 0 | 56,862 | Withhold |
| WESMARK FUNDS | 0 | 0 | 0 | 50,800 | Withhold |
| Columbia Threadneedle | 48,490 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 0 | 0 | 0 | 47,000 | Withhold |
| RMB INVESTORS TRUST | 0 | 0 | 0 | 42,460 | Withhold |
| Guggenheim | 0 | 0 | 0 | 33,569 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 31,034 | Withhold |
Showing the 25 largest of 77 asset managers. All 77 are in the interactive database (link above).
Combines 9 wordings of this item as funds reported it.
50.8% Majority: yes · of votes cast
Description as filed by funds: ELECTION OF DIRECTOR NOMINEES FOR CLASS II (term to expire in 2029): S. Kathryn Rouan, Ph.D.
Viking Therapeutics, Inc.’s own tally for this item (“Elect Director: S. Kathryn Rouan, Ph.D.”): 21,960,203 for, 21,250,268 withheld, per its Form 8-K filed May 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 50.8% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 77 asset managers below reported 12,282,280 for, 7,807,972 withheld, 907,684 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,201,249 | 0 | 112 | 450,903 | For |
| Fidelity | 1,644,087 | 0 | 0 | 4,418,663 | Mixed |
| American Century | 0 | 0 | 0 | 937,561 | Withhold |
| Charles Schwab | 707,169 | 0 | 0 | 0 | For |
| BlackRock | 0 | 0 | 664,856 | 0 | Abstain |
| Delaware/Macquarie | 0 | 0 | 0 | 330,100 | Withhold |
| JPMorgan | 312,705 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 305,414 | 0 | 0 | 0 | For |
| Principal | 0 | 0 | 0 | 280,964 | Withhold |
| State Street | 390 | 0 | 0 | 190,133 | Withhold |
| TIAA | 0 | 0 | 0 | 184,547 | Withhold |
| Lincoln Financial | 0 | 0 | 0 | 147,262 | Withhold |
| Jackson National | 0 | 0 | 114,206 | 0 | Abstain |
| First Trust | 0 | 0 | 0 | 106,325 | Withhold |
| ALPS ETF Trust | 0 | 0 | 0 | 100,464 | Withhold |
| BARON SELECT FUNDS | 0 | 0 | 0 | 74,811 | Withhold |
| MASTER INVESTMENT PORTFOLIO | 0 | 0 | 70,222 | 0 | Abstain |
| Victory Capital | 0 | 0 | 0 | 69,566 | Withhold |
| ProShares | 0 | 0 | 0 | 56,862 | Withhold |
| WESMARK FUNDS | 0 | 0 | 0 | 50,800 | Withhold |
| Columbia Threadneedle | 0 | 0 | 0 | 48,490 | Withhold |
| Erste Asset Management GmbH | 0 | 0 | 0 | 47,000 | Withhold |
| RMB INVESTORS TRUST | 0 | 0 | 0 | 42,460 | Withhold |
| Guggenheim | 0 | 0 | 0 | 33,569 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 31,034 | Withhold |
Showing the 25 largest of 77 asset managers. All 77 are in the interactive database (link above).
Combines 16 wordings of this item as funds reported it.
70% Approved · of votes cast
Prior year: 66.9% for (May 20, 2025 meeting) ▲ 3.3 pts
Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers.
Viking Therapeutics, Inc.’s own tally for this item (“3. To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement”): 30,045,938 for, 12,763,135 against — passed, per its Form 8-K filed May 26, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “As a result, the Company's stockholders voted to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.”
Support: 70% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of Viking Therapeutics, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “SAY ON PAY” (2 managers, 158 for).
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,188,385 | 463,877 | 2 | 0 | For |
| Fidelity | 6,013,895 | 48,855 | 0 | 0 | For |
| American Century | 0 | 937,561 | 0 | 0 | Against |
| Charles Schwab | 707,169 | 0 | 0 | 0 | For |
| BlackRock | 335,565 | 329,291 | 0 | 0 | Mixed |
| Delaware/Macquarie | 0 | 330,100 | 0 | 0 | Against |
| JPMorgan | 312,705 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 305,414 | 0 | 0 | 0 | For |
| Principal | 280,964 | 0 | 0 | 0 | For |
| State Street | 190,037 | 486 | 0 | 0 | For |
| TIAA | 184,547 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 147,262 | 0 | 0 | Against |
| Jackson National | 53,776 | 60,430 | 0 | 0 | Mixed |
| First Trust | 0 | 106,325 | 0 | 0 | Against |
| ALPS ETF Trust | 0 | 100,464 | 0 | 0 | Against |
| BARON SELECT FUNDS | 0 | 74,811 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 5,873 | 64,349 | 0 | 0 | Mixed |
| Victory Capital | 0 | 69,566 | 0 | 0 | Against |
| ProShares | 0 | 56,862 | 0 | 0 | Against |
| WESMARK FUNDS | 0 | 50,800 | 0 | 0 | Against |
| Columbia Threadneedle | 0 | 48,490 | 0 | 0 | Against |
| RMB INVESTORS TRUST | 0 | 42,460 | 0 | 0 | Against |
| Guggenheim | 0 | 33,569 | 0 | 0 | Against |
| Direxion Shares ETF Trust | 0 | 31,034 | 0 | 0 | Against |
| SEI | 25,312 | 1,379 | 0 | 0 | Mixed |
Fund voting reports, all 76 managers: 17,794,959 for, 3,155,829 against, 3,790 abstained, 3 not voted. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,876,698 | 0 | 0 | 0 | For |
| BlackRock | 924,366 | 1,829,343 | 0 | 0 | Mixed |
| GEODE CAPITAL MANAGEMENT, LLC | 1,766,786 | 0 | 0 | 0 | For |
| AMERIPRISE FINANCIAL INC | 0 | 1,589,304 | 0 | 0 | Against |
| American Century | 0 | 1,126,245 | 0 | 0 | Against |
| State Street | 876,021 | 10,862 | 0 | 0 | For |
| Vanguard | 856,910 | 11,279 | 0 | 0 | For |
| PNC BANK, NATIONAL ASSOCIATION | 822,250 | 0 | 0 | 0 | For |
| Charles Schwab | 719,637 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 0 | 654,294 | 0 | 0 | Against |
| Vestal Point Capital, LP | 0 | 583,407 | 0 | 0 | Against |
| Clearbridge Investments, LLC | 0 | 444,781 | 0 | 0 | Against |
| PRINCIPAL GLOBAL INVESTORS | 394,919 | 0 | 0 | 0 | For |
| STIFEL NICOLAUS & CO INC \MO\ | 0 | 372,352 | 0 | 0 | Against |
| Citadel | 349,253 | 0 | 0 | 0 | For |
| BLAIR WILLIAM & CO/IL | 0 | 336,101 | 0 | 0 | Against |
| NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST | 0 | 330,100 | 0 | 0 | Against |
| WASATCH ADVISORS LP | 312,187 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 294,587 | 0 | 0 | Against |
| DE Shaw | 0 | 278,647 | 0 | 0 | Against |
| Connor, Clark & Lunn Investment Management Ltd. | 0 | 265,442 | 0 | 0 | Against |
| RBC Dominion Securities Inc. | 0 | 228,840 | 0 | 0 | Against |
| RBC Capital Markets, LLC | 0 | 210,558 | 0 | 0 | Against |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 0 | 203,187 | 0 | 0 | Against |
| Nuveen | 199,940 | 0 | 0 | 0 | For |
Institutional-manager reports, all 347 managers: 13,955,785 for, 10,693,580 against, 22,350 abstained, 505 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
98% Approved · of votes cast
Prior year: 98.7% for (May 20, 2025 meeting) ▼ 0.3 pts
Description as filed by funds: TO RATIFY THE SELECTION OF CBIZ CPAS P.C. AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2026.
Viking Therapeutics, Inc.’s own tally for this item (“2. To ratify the selection of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2026”): 78,368,957 for, 1,241,969 against — passed, per its Form 8-K filed May 26, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “As a result, the Company's stockholders voted to ratify the selection of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2026.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 80 asset managers below reported 20,987,118 for, 8,219 against, 3,789 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,652,260 | 2 | 1 | 0 | For |
| Fidelity | 6,062,750 | 0 | 0 | 0 | For |
| American Century | 937,561 | 0 | 0 | 0 | For |
| Charles Schwab | 707,169 | 0 | 0 | 0 | For |
| BlackRock | 664,856 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 330,100 | 0 | 0 | 0 | For |
| JPMorgan | 312,705 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 305,414 | 0 | 0 | 0 | For |
| Principal | 280,964 | 0 | 0 | 0 | For |
| State Street | 190,515 | 8 | 0 | 0 | For |
| TIAA | 184,547 | 0 | 0 | 0 | For |
| Lincoln Financial | 147,262 | 0 | 0 | 0 | For |
| Jackson National | 114,206 | 0 | 0 | 0 | For |
| First Trust | 106,325 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 100,464 | 0 | 0 | 0 | For |
| BARON SELECT FUNDS | 74,811 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 70,222 | 0 | 0 | 0 | For |
| Victory Capital | 69,566 | 0 | 0 | 0 | For |
| ProShares | 56,862 | 0 | 0 | 0 | For |
| WESMARK FUNDS | 50,800 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 48,490 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 47,000 | 0 | 0 | 0 | For |
| RMB INVESTORS TRUST | 42,460 | 0 | 0 | 0 | For |
| Guggenheim | 33,569 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 31,034 | 0 | 0 | 0 | For |
Showing the 25 largest of 80 asset managers. All 80 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 116,105,643 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 8.31% |
| 2 | Fidelity | 5.22% |
| 3 | American Century | 0.81% |
| 4 | Charles Schwab | 0.61% |
| 5 | BlackRock | 0.57% |
| 6 | Delaware/Macquarie | 0.28% |
| 7 | JPMorgan | 0.27% |
| 8 | WASATCH FUNDS TRUST | 0.26% |
| 9 | Principal | 0.24% |
| 10 | State Street | 0.16% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 4.20% |
| 2 | BlackRock | 2.37% |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 1.52% |
| 4 | AMERIPRISE FINANCIAL INC | 1.37% |
| 5 | American Century | 0.97% |
| 6 | State Street | 0.76% |
| 7 | Vanguard | 0.75% |
| 8 | PNC BANK, NATIONAL ASSOCIATION | 0.71% |
| 9 | Charles Schwab | 0.62% |
| 10 | PICTET ASSET MANAGEMENT SA | 0.56% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Vanguard Group | 9,984,487 | 8.60% | Form 13F, quarter ended March 31, 2026 |
| BlackRock | 6,880,290 | 5.93% | Form 13F, quarter ended March 31, 2026 |
| FMR (Fidelity) | 6,024,753 | 5.19% | Form 13F, quarter ended March 31, 2026 |
| FMR LLC | 5,772,050 | 4.97% | Proxy statement (DEF 14A), table as of March 15, 2026 |
| Two Sigma | 4,432,142 | 3.82% | Form 13F, quarter ended March 31, 2026 |
| State Street | 4,395,557 | 3.79% | Form 13F, quarter ended March 31, 2026 |
| Brian Lian, Ph.D. | 4,139,349 | 3.57% | Proxy statement (DEF 14A), table as of March 15, 2026 |
| Morgan Stanley | 3,076,270 | 2.65% | Form 13F, quarter ended March 31, 2026 |
| Citadel Advisors | 2,615,121 | 2.25% | Form 13F, quarter ended March 31, 2026 |
| D.E. Shaw | 1,676,713 | 1.44% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 116,105,643 shares outstanding, as reported by Viking Therapeutics, Inc. on its Form 10-Q dated April 15, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Viking Therapeutics, Inc.'s shareholder meeting held May 19, 2026, in the 2025-2026 proxy season, 408 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 1,609 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers. — Viking Therapeutics, Inc.'s filing reports the proposal as approved, with 70% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Viking Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 26, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Viking Therapeutics, Inc.’s 10-Q dated April 15, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Viking Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Viking Therapeutics (VKTX) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/viking-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.